Industry Focus

Amgen has shelved its once-promising psoriasis drug. Motley Fool's Michael Douglass and Todd Campbell help investors understand the impact.

Direct download: 150527_IF_Healthcare.mp3
Category:Podcast -- posted at: 4:41pm EDT